# US 2021/0198264 A1 · Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198264 A1
- Document ID: US20210198264A1
- Status: Published application
- Kind: A1
- Application number: 17/125,384
- Filed: 2020-12-17
- Published: 2021-07-01
- Earliest claimed: 2019-12-20
- Assignees: Principia Biopharma Inc.
- Applicants: Principia Biopharma Inc.
- Inventors: Pasit Phiasivongsa; Katherine Chu; Jiang Zhu; Kolbot By; Mohammad Reza Masjedizadeh
- Web page: https://patentgrep.com/patent/US20210198264A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.

## Claims

### Claim 1

A solid form of Compound (I)
characterized by a mean bulk density greater than 0.3 g/cc.

### Claim 2 (depends on 1)

The solid form according to claim 1, characterized by a mean tapped density between 0.7 g/cc and 0.9 g/cc.

### Claim 3 (depends on 1)

The solid form according to claim 1, characterized by a Hausner ratio less than or equal to 1.2.

### Claim 4 (depends on 1)

The solid form according to claim 1, characterized by:
a wet particle size distribution having a D10 value greater than 70 μm;
a wet particle size distribution having a D50 value greater than 200 μm; and/or
a wet particle size distribution having a D90 value greater than 400 μm.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The solid form according to claim 1, characterized by:
a mass loss of less than 5 wt. % between 20° C. and 240° C. by thermogravimetric analysis; and/or
a glass transition temperature (Ta) greater than 90° C. at 0% relative humidity.

### Claim 8 (depends on 1)

The solid form according to claim 1, wherein the total level of residual solvents in the solid form is less than 1%.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The solid form according to claim 1, wherein:
the residual methanol level is less than 3000 ppm;
the residual isopropyl acetate level is less than 5000 ppm;
the residual heptane level is less than 5000 ppm; and/or
the residual dichloromethane level is less than 1500 ppm.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The solid form according to claim 1, wherein the solid form is substantially amorphous.

### Claim 14

A solid form of Compound (I)
characterized by a wet particle size distribution having a D10 value less than 10 μm.

### Claim 15 (depends on 14)

The solid form according to claim 14, characterized by:
a wet particle size distribution having a D10 value between 5 μm and 6 μm or a D10 value between 1 and 2 μm;
a wet particle size distribution having a D50 value less than 100 μm; and/or
a wet particle size distribution having a D90 value less than 200 μm.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 14)

The solid form according to claim 14, characterized by:
a mean bulk density less than 0.3 g/cc; and/or
a mean tapped density less than 0.3 q/cc.

### Claim 19

(canceled)

### Claim 20 (depends on 14)

The solid form according to claim 14, characterized by:
a mass loss of less than 5 wt. % between 20° C. and 240° C. by thermogravimetric analysis; and/or
a glass transition temperature (Tg) greater than 90° C. at 0% relative humidity.

### Claim 21 (depends on 14)

The solid form according to claim 14, wherein the total level of residual solvents in the solid form is less than 1%.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 14)

The solid form according to claim 14, wherein:
the residual methanol level is less than 500 ppm;
the residual isopropyl acetate level is less than 4000 ppm;
the residual heptane level is less than 500 ppm; and/or
the residual dichloromethane level is less than 1500 ppm.

### Claim 25

(canceled)

### Claim 26 (depends on 14)

The solid form according to claim 14, wherein the solid form is substantially amorphous.

### Claim 27

A process for preparing a solid form of Compound (I) comprising:
washing a solution comprising Compound (I) and an organic solvent with an aqueous solution of a weak organic acid having a pKa less than or equal to 7 to create a first solution comprising a first organic layer and a first aqueous layer; and
removing the first aqueous layer, leaving behind the first organic layer comprising Compound (I).

### Claim 28 (depends on 27)

The process according to claim 27, further comprising:
adding a strong acid to the first organic layer;
concentrating the first organic layer by removing the organic solvent to provide a residue comprising Compound (I); and
washing the residue comprising Compound (I) with water or an aqueous salt solution.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The process according to claim 28, further comprising:
adding a water-immiscible organic solvent to provide a second organic layer, and a second aqueous layer comprising Compound (I); and
removing the second organic layer.

### Claim 31

(canceled)

### Claim 32 (depends on 28)

The process according to claim 28, further comprising:
adjusting the pH of the first or second aqueous layer to a value between 1 and 5 by adding an aqueous base;
determining a level of residual weak organic acid having a pKa less than or equal to 7 in the first or second aqueous layer; and
adjusting the level of the weak organic acid having a pKa less than or equal to 7 to 0 wt. % to 8 wt. %.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The process according to claim 32, further comprising:
adding an aqueous base to the first or second aqueous layer to obtain a pH between 8 and 11 and allowing a precipitate comprising Compound (I) to form;
isolating the precipitate comprising Compound (I) by filtering; and
washing the precipitate comprising Compound (I) with water.

### Claim at position 35

35-37. (canceled)

### Claim 38

A process for preparing a solid form of Compound (I) comprising:
dissolving a crystalline form of Compound (I) in a solution comprising a water-immiscible organic solvent and brine;
adding one equivalent of a strong acid to create an aqueous layer and an organic layer;
removing the organic layer;
concentrating the aqueous layer;
adding an aqueous base to adjust the pH to a value between 8 and 11 to obtain a precipitate of a solid form of Compound (I);
isolating the precipitate of the solid form of Compound (I) by filtering;
rinsing the precipitate with water; and
drying the precipitate to obtain a solid form of Compound (I).

### Claim 39 (depends on 38)

The process according to claim 38, further comprising micronizing particles of Compound (I).

### Claim 40

A process for preparing an amorphous form of Compound (I) comprising:
washing a solution of Compound (I) with a first aqueous acidic solution to create a first solution comprising a first organic layer and a first aqueous layer, wherein the solution of Compound (I) comprises a first organic solvent;
removing the first aqueous layer; and
performing a solvent exchange from the first organic solvent to a second organic solvent.

### Claim 41 (depends on 40)

The process according to claim 40, further comprising:
washing the first organic layer with a second aqueous acidic solution to create a second solution comprising a second organic layer and a second aqueous layer, wherein the second aqueous layer comprises Compound (I); and
removing the second organic layer.

### Claim 42 (depends on 41)

The process according to claim 41, further comprising:
adding a first base to the second aqueous layer to create a third solution comprising a third organic layer and a third aqueous layer, wherein the third organic layer comprises Compound (I);
extracting the third aqueous layer using a third organic solvent;
concentrating the third organic layer;
adding an antisolvent to the third organic layer to create a precipitate comprising Compound (I); and
isolating the precipitate comprising Compound (I).

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 42)

The process according to claim 42, further comprising:
dissolving the precipitate comprising Compound (I) in a fourth organic solvent to create a fourth solution; and
spray drying the fourth solution to obtain a solid form of Compound (I).

### Claim 46 (depends on 45)

The process according to claim 45, further comprising micronizing the solid form of Compound (I).

### Claim 47 (depends on 1)

A pharmaceutical composition comprising:
a solid form of Compound (I) according to claim 1; and
at least one pharmaceutically acceptable excipient.

### Claim 48 (depends on 1)

A method of inhibiting Bruton's tyrosine kinase (BTK) in a mammal in need of such BTK inhibition comprising administering to the mammal a therapeutically effective amount of a solid form of Compound (I) according to claim 1.

### Claim 49 (depends on 1)

A method of treating pemphigus vulgaris, pemphigus foliaceus, or immune thrombocytopenia in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a solid form of Compound (I) according to claim 1.

### Claim 50

(canceled)
